# Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes

> **NCT00383578** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 335 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin 100 mg qd
- **DRUG:** Metformin 1500 mg daily

## Key facts

- **NCT ID:** NCT00383578
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383578, "Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00383578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*